nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

23.05.2016 | Letter to the Editor

Developing more effective, non-neurotoxic, methotrexate-based therapy in infants with brain tumors

verfasst von: Ian J. Cohen

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Lucchesi ML, Guidi M, Fonte C, Farina S, Fiorini P, Favre C, de Martino M, Sardi I (2016) Pharmacokinetics of high-dose methotrexate in infants less than 12 months treated for aggressive brain tumors. Cancer Chemother Pharmacol 77:857–864CrossRefPubMed

Morse M, Savitch J, Balis F, Miser J, Feusner J, Reaman G, Poplack D, Bleyer A (1985) Altered central nervous system pharmacology of methotrexate in childhood leukemia; another sign of meningeal relapse. J Clin Oncol 3:19–24PubMed

Pollock RJ, Kaufman S (1978) Dihydrofolate is present in the brain. Neurochem 30:253–256CrossRef

Poplack DG, Bleyer WA, Wood JH, Kostolich M, Savitch JL, Ommaya AK (1977) A primate model to study pharmacokinetics in the central nervous system. Cancer Res 37:1982–1985PubMed

Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Ludz P, Coze C, Perel Y, Raphael M, Terrier M et al (2001) THE SOCIETE francaise d’Óncologie pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379CrossRefPubMed

Sirotnak FM, Moccio DM, Dorick DM (1978) Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 38:345–353PubMed

Cohen IJ (2007) Prevention of high-dose—methorexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation. Med Hypotheses 68:1147–1153CrossRefPubMed

Cohen IJ (2013) Challenging the clinical relevance of folinic acid over rescue after high dose MTX. Med Hypotheses 81:942–947CrossRefPubMed

Borsi JD, Wesenberg F, Stokland T, Moe PJ (1991) How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukemia. Eur J Cancer 27:1006–1009CrossRefPubMed

10.

Bonda-Shkedi E, Weyl Ben Harush M, Kaplinsky C, Ash S, Goshen Y, Yaniv I, Cohen IJ (2013) The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated with osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study. J Pediatr Hematol Oncol 35:271–275CrossRefPubMed

11.

Spiegler BJ, Kimberly K, Maze R, Greenberg ML, Weitzman S, Hitzler JK, Nathan PC (2006) Comparison of long term neurocognitive outcome in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high dose intravenous methotrexate. J Clin Oncol 24:3858–3864CrossRefPubMed

Titel: Developing more effective, non-neurotoxic, methotrexate-based therapy in infants with brain tumors
verfasst von: Ian J. Cohen
Publikationsdatum: 23.05.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3053-3

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Developing more effective, non-neurotoxic, methotrexate-based therapy in infants with brain tumors

Excerpt

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer

Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1

Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials

Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours

Combinational strategies of metformin and chemotherapy in cancers

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie